Mohammed Saif
Internal Medicine · Freeport, NYNPI 1275562415
Payments from drug & device makers
Across 90 payments — averaging $40.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novartis$337
- Pfizer$315
- Johnson & Johnson$250
- Acadia Pharmaceuticals Inc$241
- AstraZeneca$231
- plus $720 from 15 others
What the payments were for
- Speaking & faculty fees$1,39038%
- Food & beverage$2,25562%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 5 | $1,551 |
| Novartis | 20 | $337 |
| Pfizer | 17 | $315 |
| Johnson & Johnson | 3 | $250 |
| Acadia Pharmaceuticals Inc | 2 | $241 |
| AstraZeneca | 2 | $231 |
| Kowa Pharmaceuticals America, Inc. | 11 | $172 |
| Novo Nordisk | 7 | $121 |
| Amgen | 5 | $95 |
| Siemens Medical Solutions USA, Inc. | 1 | $62 |
| Merck | 4 | $55 |
| Esperion Therapeutics, Inc. | 3 | $43 |
| Seqirus USA Inc | 2 | $26 |
| Eisai Inc. | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $20 |
| Biocryst US Sales Co., LLC | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Astellas Pharma US Inc | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Medicure Pharma Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,645 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 288 | $165,506 |
| JanuviaSitagliptin Phosphate | 304 | $109,799 |
| Invega SustennaPaliperidone Palmitate | 32 | $93,091 |
| OzempicSemaglutide | 43 | $40,745 |
| JanumetSitagliptin Phos/Metformin Hcl | 32 | $40,220 |
| XareltoRivaroxaban | 78 | $34,751 |
| RexultiBrexpiprazole | 38 | $27,381 |
| Divalproex Sodium | 506 | $26,406 |
| Risperdal ConstaRisperidone Microspheres | 16 | $25,589 |
| JardianceEmpagliflozin | 46 | $22,796 |
| Clozapine | 138 | $19,560 |
| LokelmaSodium Zirconium Cyclosilicate | 28 | $16,892 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 129 | $15,656 |
| Valproic AcidValproic Acid (As Sodium Salt) | 185 | $12,158 |
| FarxigaDapagliflozin Propanediol | 15 | $10,728 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $315 | $165,506288 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto, Risperdal Consta | $250 | $153,431126 claims |
| MerckJanuvia, Janumet | $55 | $150,018336 claims |
| Novo NordiskOzempic | $121 | $40,74543 claims |
| AstraZenecaLokelma, Farxiga | $231 | $27,62043 claims |
| Lilly USA, LLCOlanzapine | $16 | $4,425172 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Freeport
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.